Japanese drugmaker Eisai and U.S biotech company Biogen said in a joint statement on Monday that the Ministry of Health, Labor and Welfare granted priority review status for their treatment of Alzheimer s disease.
The drug, Lecanemab, was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of patients in the early stages of the mind-wasting disease.
The companies said priority review in Japan is given to new medicines recognized as having high medical utility for serious diseases. Once the priority status has been granted, the target total review period is shortened, they said.
This could be due to a conflict with your ad blocker or security software. There is a list of allowed sites for piano and jp.io. If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this FAQ. We apologize for the inconvenience.